“…Nonetheless, based on previous studies (18,19,76) addressing hsCRP, this biomarker has been considered for adoption into risk assessment algorithms (77). Recently conducted studies have, however, shown that the predictivity of hsCRP is attenuated when tested in a multivariable model in the general population (78), and together with natriuretic peptides in patients with known CAD (79)(80)(81)(82). In our study, hsCRP appears to be a potential predictor for all-cause mortality, also when adjusted for BNP, but does not reflect cardiac strength of our study is the absence of patients lost to follow-up; in fact, there were only four patients with no measurements available for hsCRP.…”